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and literature sources. Two price scenarios were evaluated, one in which the sutureless 
valve is sold at the double, and one at the triple price of its comparator. Future costs and 
outcomes are discounted at a yearly 3.5% rate. Results: In the first cost scenario, the 
model predicts that on average MiAVR with Perceval S instead of traditional sutured 
valves in FS would yield incremental 0.29 LYs (0.20 QALYs) and savings for about 3,000 
€ and 3,250 £, in France and UK, respectively. In the second cost scenario, Perceval S 
in MiAVR still remains dominant, with savings for 550 € and 740 £, in France and UK, 
respectively. Deterministic threshold analysis indicates that the sutureless valve would 
retain acceptable cost-effectiveness (at willingness-to-pay thresholds of 30,000€ and 
20,000£ per QALY) as long as its price does not exceed 5.6 and 4.9 times that of the 
traditional valve, in France and UK, respectively. ConClusions: The sutureless valve 
in combination with MiAVR offers the opportunity to improve outcomes in isolated 
AVR at a reduced cost to the third party payers.
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Serum total and LDL cholesterol levels are high (13.9% for borderline high LDL- choles-
terol) and increasing in China. Hyperlipidemia is a main risk factor for cardiovascular 
and cerebrovascular diseases. Screening is one of the effective prevention methods; 
however, there has been no appraisal of the cost-effectiveness of blood lipid screen-
ing in China. objeCtives: To determine the cost-utility of blood lipid screening and 
subsequent interventions versus no screening for the prevention and treatment of 
hyperlipidemia and its complication. Methods: Cost utility analysis based on a 
Markov model was conducted for a cohort of Chinese adults aged 45 and abovefrom 
screening to death. Published clinical trials and epidemiological studies retrieved from 
electronic bibliographic databases; supplementary data obtained from CVD patients 
survey in China. Markov model simulated the long term effects of screening and no 
screening strategies from the aspects of cost and effectiveness. The model assumed a 
30 year time horizon, and costs and benefits were discounted at 5%. The willingness-
to-pay threshold is ¥100,000/QALY. Sensitivity analyses were conducted to evaluate 
assumptions of the model and to identify which model inputs had most impact on the 
results. Results: Estimated costs for each quality adjusted life year (QALY) gained 
among no screening population were ¥6325.8, with cumulative costs of ¥77112 and 
cumulative utility of 12.19, and ¥5783.5 for screened population with cumulative costs 
of ¥72178 and cumulative utility of 12.48, respectively. The results showed the blood 
lipid screening was associated with increased QALY and potentially cost-saving as 
compared with no screening. Sensitivity analyses demonstrated robustness of the 
results. ConClusions: Based on this Markov model, blood lipid screening is likely 
to be cost-effective option compared with no screening for the prevention and treat-
ment of hyperlipidemia and its complication among Chinese aged 45 and above.
PCV108
Cost-effeCtiVeness of drUg-elUting stents VersUs bAre metAl 
stents in egyPtiAn diAbetiC PAtients
ElSisi G., Ragab S., Ashraf R., Elmahdawy M.
Central Administration for Pharmaceutical Affairs, Cairo, Egypt
objeCtives: Cost-effectiveness of Drug eluting stents (DES) versus bare metal stents 
(BMS) in Egyptian diabetic patients with chronic coronary artery disease from a 
patient perspective was evaluated over a time horizon of 3 years. Methods: A cohort 
Markov process model with five health states: stent, coronary artery bypass surgery 
(CABG), non-fatal myocardial infarction (MI), percutaneous coronary intervention 
(PCI) and death was derived from published data. The transition probabilities from the 
index procedure to death, MI, PCI, and CABG were derived from an updated, previously 
published meta-analysis of RCTs comparing DES with BMS in patients with coronary 
artery disease. Relative risk reduction, restenosis risks, mortality rates, utilities were 
derived using published sources. Direct Medical costs were obtained from 4 top-rated 
cardiology hospitals in Egypt. All costs and effects were discounted at 3.5% annually. 
All costs were reported in Egyptian pounds of the financial year 2013. Deterministic 
sensitivity analysis was conducted. Results: In the overall population, total costs for 
DES and BMS were 20,664 EGP and 11,957 EGP respectively. Total QALYs for DES and 
BMS were 2.26 and 2.05 respectively. The incremental cost-effectiveness ratio (ICER) 
for DES versus BMS was 41,616 EGP/QALY. DES is cost effective because it is less than 
3 times GDP/capita in Egypt (57,566 EGP). Results between DES and BMS were most 
sensitive to the Mortality rate of both DES and BMS. ConClusions: World Health 
Organization recommends that interventions that cost more than 3 times GDP/capita 
for one Disability Adjusted Life Year (DALY) avoided should not be reimbursed. Despite 
DALY is different from QALY but we can assume that they are similar to be able to put 
a value on the outcome. DES represents a good value for money compared to BMS in 
Egyptian diabetic patients with chronic coronary artery disease.
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objeCtives: Using statins in primary prevention is controversial given the low event 
rate and the difficulty to identify patients who really benefit. Coronary calcium score 
has been identified as a strong predictor of cardiovascular events, being recom-
mended for risk stratification in intermediate risk individuals. This study aims to 
assess, from the Portuguese societal perspective, the cost-utility of determining coro-
nary calcium score to guide the use of statins in individuals with elevated C-reactive 
protein and low LDL cholesterol. Three strategies are compared: no treatment, test 
and treat accordingly, and treat every patient with rosuvastatin 20mg. Methods: 
discontinuations and death. Main outcomes were quality adjusted life years (QALY) 
and costs. Univariate and probabilistic sensitivity analyses (PSA) were conducted on 
the incremental cost-effectiveness ratio (ICER). Results: In the base-case analysis, 
apixaban treatment compared to VKAs has an ICER well below an informal mini-
mal willingness-to-pay threshold of € 20,000/QALY for The Netherlands (i.e. around 
€ 7,000/QALY). PSA showed that the results of the base-case analysis were quite 
robust. Potentials exist for apixaban to be dominant over the other NOACs, rivaroxa-
ban and dabigatran depending on hazard ratios, risks for complications and local 
price levels. patients in The Netherlands. ConClusions: In patients with AF, we 
found apixaban to be a cost-effective option in The Netherlands, compared to VKAs.
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objeCtives: Several cost-effectiveness analyses exist that compare rivaroxaban 
with enoxaparin sodium as thrombosis prophylaxis in patients undergoing total 
hip replacement (THR) or total knee replacement (TKR) surgery. However, none of 
these refers to a societal perspective, and thus indirect costs have so far not yet 
been included. The objective of this research was to conduct a cost-utility analysis 
from the German societal perspective, based on a life-time horizon. Methods: A 
decision-tree was used to calculate the short term consequences of treatmentby 
classifying whether subjects experienced a deep a vein thrombosis, a pulmonary 
embolism, a major bleeding, death due to the surgery, or no event. Furthermore, 
we designed a Markov model to quantify the long-term consequences. The main 
health effect was based on the RECORD 1 and RECORD 3 trials. A semi-micro simu-
lation approach was applied to reflect the age and gender distribution of the target 
population. Probabilistic, deterministic and structural sensitivity analyses were per-
formed to assess the robustness of the results. Results: Rivaroxaban dominated 
enoxaparin sodium in the case of TKR. This dominance was robust within sensitivity 
analysis. In contrast, the point estimate of the cost-effectiveness ratio in the case of 
THR was € 867,018 per quality-adjusted life year (QALY). However, there was a wide 
variation within the probabilistic sensitivity analysis: the dots were substantially 
scattered over three quadrants of the cost-effectiveness plane. Compared to previ-
ous analyses, the selection of effectiveness data seems to have a significant impact 
of the results. ConClusions: Rivaroxaban was found to dominate enoxaparin 
sodium after TKR, whereas the evidence regarding THR is unclear. Results were 
similar to previous analyses from the third-party payer perspective.
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objeCtives: To estimate the cost-effectiveness of home telemonitoring (TM) or 
structured telephone support (STS) strategies versus usual care for adults recently 
discharged (within 28 days) after a heart failure (HF) exacerbation in England and 
Wales. Methods: A Markov model was used to evaluate a) STS via human to 
machine (HM) interface, b) STS via human to human (HH) contact, and c) TM, against 
d) usual care. Given heterogeneity in the interventions, cost-effectiveness analysis 
was performed using bottom up costing scenarios regarding costs of devices, moni-
toring and medical care to deal with alerts. Costs and quality adjusted life years 
(QALYs) over a 30 year (patient lifetime) horizon were estimated based on monthly 
probabilities of death and monthly risks of hospitalisations (HF-related complica-
tions or other causes) estimated from clinical effectiveness parameters computed 
using a network meta-analysis of randomised controlled trials. Results: Base case 
monthly costs per patient were: £27 for usual care, £119 for STS HM, £179 for STS HH 
and £175 for TM. TM was the most cost-effective strategy in the scenario using these 
base case costs. Compared with usual care, TM had an estimated incremental cost 
effectiveness ratio (ICER) of £9,552/QALY, whereas STS HH had an ICER of £63,240/
QALY against TM. STS HM was dominated by usual care. Probabilistic sensitivity 
analysis (PSA) showed 44% chance of TM being cost-effective at a willingness to 
pay threshold of £20,000 per QALY, with STS HH 36%, STS HM 18% and usual care 
2%, respectively. Scenario analyses performed using higher costs of usual care, 
higher costs of STS HH and lower costs of TM do not substantially change the con-
clusions. ConClusions: Cost-effectiveness analyses suggest TM was an optimal 
strategy in most scenarios, but there is considerable uncertainty in relation to clear 
descriptions of the interventions and robust estimation of costs.
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objeCtives: Mini-invasive aortic valve replacement (MiAVR) has several advantages 
over full sternotomy (FS), mainly less surgical trauma, decreased blood loss, lower 
mortality and faster recovery. Perceval S is an aortic valve which is implanted without 
need for suturing and a collapsed profile, thus allowing a significant reduction of cross-
clamping times, an independent risk factor for worse outcomes, allowing to expand 
the pool of operable patients with MiAVR. Methods: A patient-level simulation model 
fully coded in WinBugs was updated and extended to predict lifetime effectiveness 
and costs of isolated AVR procedures associated with this new valve in France and 
UK, as compared to traditional valve implants, from the cost perspective of the third 
party payer. Unit costs and health state-specific utilities were retrieved from official 
